Status: Recruiting
PRO-232 in Patients Subjected to Cataract Surgery
The main objective of this study is to evaluate the efficacy and safety of the PRO-232 formulation manufactured by Laboratorios Sophia S.A. de C.V. on the ocular surface of postoperative cataract patients versus a concomitant administration of ophthalmic moxifloxacin and dexamethasone.
Participants needed: 134
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Laboratorios Sophia S.A de C.V.Updated: Dec 26, 2025Locations: 2
Eligibility criteria
To have the ability to voluntarily grant their signed informed consent (FCI). [+7]
Allergy to any of the components of the investigational products or to any of th... [+27]